Inozyme Pharma(INZY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INZY Inozyme Pharma

交易中 11-15 10:20:13 EST

3.26

-0.17

-4.96%

最高3.48	最低3.26	成交量7.61万
今开3.48	昨收3.43	日振幅6.41%
总市值2.09亿	流通市值1.28亿	总股本6,424万
成交额25.28万	换手率0.19%	流通股本3,938万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"INZY","market":"US","secType":"STK","nameCN":"Inozyme Pharma","latestPrice":3.26,"timestamp":1731683984535,"preClose":3.43,"halted":0,"volume":76107,"delay":0,"floatShares":39380500,"shares":64240198,"eps":-1.550867,"marketStatus":"交易中","marketStatusCode":2,"change":-0.17,"latestTime":"11-15 10:20:13 EST","open":3.48,"high":3.48,"low":3.26,"amount":252819.9041856,"amplitude":0.06414,"askPrice":3.28,"askSize":105,"bidPrice":3.26,"bidSize":208,"shortable":3,"etf":0,"ttmEps":-1.550867,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1731704400000},"adr":0,"listingDate":1595563200000,"adjPreClose":3.43,"preHourTrading":{"tag":"盘前","latestPrice":3.65,"preClose":3.43,"latestTime":"08:14 EST","volume":5,"amount":18.25,"timestamp":1731676455932},"postHourTrading":{"tag":"盘后","latestPrice":3.6,"preClose":3.43,"latestTime":"18:56 EST","volume":11589,"amount":39803.6101,"timestamp":1731628587855},"volumeRatio":2.031867,"impliedVol":3.7998,"impliedVolPercentile":0.9762},"requestUrl":"/m/hq/s/INZY","defaultTab":"news","newsList":[{"id":"2483515478","title":"Inozyme Pharma, Inc.盘中异动 股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483515478","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483515478?lang=zh_cn&edition=full","pubTime":"2024-11-14 03:43","pubTimestamp":1731526982,"startTime":"0","endTime":"0","summary":"北京时间2024年11月14日03时43分，Inozyme Pharma, Inc.股票出现异动，股价大幅下挫5.05%。Inozyme Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.44%。Inozyme Pharma, Inc.公司简介：Inozyme Pharma 是一家临床阶段的罕见病生物制药公司，致力于开发用于治疗影响血管、软组织和骨骼疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111403430398e42730&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111403430398e42730&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2482678702","title":"Inozyme Pharma, Inc.2024财年第三财季实现净利润-24.57百万美元，同比减少47.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482678702","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482678702?lang=zh_cn&edition=full","pubTime":"2024-11-11 00:00","pubTimestamp":1731254425,"startTime":"0","endTime":"0","summary":"11月11日，Inozyme Pharma, Inc.公布财报，公告显示公司2024财年第三财季净利润为-24.57百万美元，同比减少47.66%；其中营业收入为0.00美元，每股基本收益为-0.39美元。从资产负债表来看，Inozyme Pharma, Inc.总负债60.57百万美元，其中短期债务4.56百万美元，资产负债比为0.03，流动比率为0.08。机构评级：截至2024年11月11日，当前有8家机构对Inozyme Pharma, Inc.目标价做出预测，其中目标均价为18.75美元，其中最低目标价为12.00美元，最高目标价为43.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000033abb3620d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000033abb3620d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY"],"gpt_icon":0},{"id":"2481624519","title":"美国研究综述-阿波罗、Booking Holdings、Portillos","url":"https://stock-news.laohu8.com/highlight/detail?id=2481624519","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481624519?lang=zh_cn&edition=full","pubTime":"2024-11-06 17:15","pubTimestamp":1730884501,"startTime":"0","endTime":"0","summary":"    路透11月6日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括阿波罗、Booking Holdings 和 Portillos。要闻 * 阿波罗  ：摩根大通将目标价从143美元上调至161美元 * Aris Water Solutions Inc   ：摩根大通将其评级从 \"增持 \"下调至 \"中性  * Booking Holdings Inc   ：Truist Securities将目标价从4100美元上调至4700美元  * Choice Hotels International Inc   ：杰富瑞将其评级从 \"买入 \"下调至 \"持有  * Portillos Inc   ：Stifel将其评级从 \"买入 \"下调至 \"持有  以下是路透周三报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FRPT","BRKR","BVS","BEAM","ACLX","BK4141","ARIS","FIS","LU0029874061.USD","BOW","LU0426417589.USD","EXAS","LU0390134368.USD","GFS","INZY","ADUS","AGCO","CC","ANAB","LU0708994859.HKD","GO","HPK","GXO","CMI","IT","EMN","AHCO","AIG","DBRG","EMR","CTRE","CHH","ABBV","ALL","AZPN","APO","MO","ABNB","BK4113","AVB","LU2065169927.USD","BR","APLS","BLDR","LU0868494708.USD","CE","AMH","LU2065171311.SGD","BKNG","GMED"],"gpt_icon":0},{"id":"2481761403","title":"Inozyme Pharma Inc 报告截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2481761403","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481761403?lang=zh_cn&edition=full","pubTime":"2024-11-06 12:58","pubTimestamp":1730869088,"startTime":"0","endTime":"0","summary":"   * Inozyme Pharma Inc   报告，截至9月30日的季度调整后每股亏损39美分，低于去年同期的每股收益-29美分。九位分析师对该季度的平均预期是每股亏损 44 美分。华尔街预期为每股-46美分至-41美分。* Inozyme Pharma Inc 公布的季度每股收益为亏损 39 美分。* Inozyme Pharma Inc 本季度股价下跌了 15.5%，今年迄今为止上涨了 3.8%。华尔街对 Inozyme Pharma Inc 的 12 个月目标价中位数为 15.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Inozyme Pharma Inc 报告截至 9 月 30 日的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2480581506","title":"Inozyme Pharma, Inc.盘中异动 早盘股价大涨8.75%报4.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480581506","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480581506?lang=zh_cn&edition=full","pubTime":"2024-11-04 22:31","pubTimestamp":1730730689,"startTime":"0","endTime":"0","summary":"北京时间2024年11月04日22时31分，Inozyme Pharma, Inc.股票出现异动，股价快速拉升8.75%。Inozyme Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。Inozyme Pharma, Inc.公司简介：Inozyme Pharma 是一家临床阶段的罕见病生物制药公司，致力于开发用于治疗影响血管、软组织和骨骼疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104223133a215492e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104223133a215492e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2480805448","title":"Inozyme Pharma Inc   预计每股亏损44美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2480805448","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480805448?lang=zh_cn&edition=full","pubTime":"2024-11-01 22:52","pubTimestamp":1730472759,"startTime":"0","endTime":"0","summary":"   * Inozyme Pharma Inc    预计在11月5日公布截至2024年9月30日的业绩时，季度收入将没有变化(预计)。*    * LSEG分析师对Inozyme Pharma Inc的平均预期是每股亏损44美分。* 目前，分析师对该公司股票的平均评级为 \"买入\"，建议分类为 9 个 \"强烈买入 \"或 \"买入\"，没有 \"持有\"，也没有 \"卖出 \"或 \"强烈卖出\"。* 华尔街对 Inozyme Pharma Inc 的 12 个月目标价中位数为 15.50 美元，高于其最新收盘价 4.29 美元。11月1日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Inozyme Pharma Inc   预计每股亏损44美分 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY"],"gpt_icon":0},{"id":"2480066134","title":"Inozyme Pharma, Inc.盘中异动 大幅下挫5.07%报4.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480066134","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480066134?lang=zh_cn&edition=full","pubTime":"2024-11-01 03:55","pubTimestamp":1730404526,"startTime":"0","endTime":"0","summary":"北京时间2024年11月01日03时55分，Inozyme Pharma, Inc.股票出现异动，股价大幅下跌5.07%。Inozyme Pharma, Inc.股票所在的生物技术行业中，整体跌幅为3.00%。Inozyme Pharma, Inc.公司简介：Inozyme Pharma 是一家临床阶段的罕见病生物制药公司，致力于开发用于治疗影响血管、软组织和骨骼疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101035526ab8d3801&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101035526ab8d3801&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2479236765","title":"Inozyme Pharma, Inc.盘中异动 大幅下挫5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479236765","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479236765?lang=zh_cn&edition=full","pubTime":"2024-10-30 00:26","pubTimestamp":1730219210,"startTime":"0","endTime":"0","summary":"北京时间2024年10月30日00时26分，Inozyme Pharma, Inc.股票出现波动，股价急速下跌5.23%。Inozyme Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.13%。Inozyme Pharma, Inc.公司简介：Inozyme Pharma 是一家临床阶段的罕见病生物制药公司，致力于开发用于治疗影响血管、软组织和骨骼疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103000265098e3f273&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103000265098e3f273&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2469149333","title":"Inozyme Pharma, Inc.盘中异动 大幅下挫5.03%报5.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2469149333","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469149333?lang=zh_cn&edition=full","pubTime":"2024-09-23 23:07","pubTimestamp":1727104040,"startTime":"0","endTime":"0","summary":"北京时间2024年09月23日23时07分，Inozyme Pharma, Inc.股票出现异动，股价急速下跌5.03%。Inozyme Pharma, Inc.股票所在的生物技术行业中，整体跌幅为1.13%。Inozyme Pharma, Inc.公司简介：Inozyme Pharma 是一家临床阶段的罕见病生物制药公司，致力于开发用于治疗影响血管、软组织和骨骼疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240923230721a1dbf085&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240923230721a1dbf085&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2460004884","title":"Inozyme Pharma, Inc.盘中异动 早盘大幅上涨5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460004884","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460004884?lang=zh_cn&edition=full","pubTime":"2024-08-20 21:36","pubTimestamp":1724160997,"startTime":"0","endTime":"0","summary":"北京时间2024年08月20日21时36分，Inozyme Pharma, Inc.股票出现波动，股价大幅拉升5.25%。Inozyme Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.13%。Inozyme Pharma, Inc.公司简介：Inozyme Pharma 是一家临床阶段的罕见病生物制药公司，致力于开发用于治疗影响血管、软组织和骨骼疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082021363898e35847&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082021363898e35847&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2460034481","title":"Inozyme Pharma, Inc.盘中异动 早盘股价大涨12.99%报5.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460034481","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460034481?lang=zh_cn&edition=full","pubTime":"2024-08-19 21:31","pubTimestamp":1724074304,"startTime":"0","endTime":"0","summary":"北京时间2024年08月19日21时31分，Inozyme Pharma, Inc.股票出现波动，股价急速拉升12.99%。Inozyme Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Inozyme Pharma, Inc.公司简介：Inozyme Pharma 是一家临床阶段的罕见病生物制药公司，致力于开发用于治疗影响血管、软组织和骨骼疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081921314495a715d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081921314495a715d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2459477389","title":"Inozyme Pharma, Inc.2024财年第二财季实现净利润-27.03百万美元，同比减少73.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459477389","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459477389?lang=zh_cn&edition=full","pubTime":"2024-08-16 00:02","pubTimestamp":1723737778,"startTime":"0","endTime":"0","summary":"8月16日，Inozyme Pharma, Inc.公布财报，公告显示公司2024财年第二财季净利润为-27.03百万美元，同比减少73.49%；其中营业收入为0.00美元，每股基本收益为-0.44美元。从资产负债表来看，Inozyme Pharma, Inc.总负债61.29百万美元，其中短期债务959000.00美元，资产负债比为0.03，流动比率为0.10。机构评级：截至2024年8月16日，当前有7家机构对Inozyme Pharma, Inc.目标价做出预测，其中目标均价为19.43美元，其中最低目标价为13.00美元，最高目标价为40.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816000318959be68b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816000318959be68b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY"],"gpt_icon":0},{"id":"2459476187","title":"Inozyme Pharma, Inc.盘中异动 早盘股价大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459476187","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459476187?lang=zh_cn&edition=full","pubTime":"2024-08-15 22:49","pubTimestamp":1723733349,"startTime":"0","endTime":"0","summary":"北京时间2024年08月15日22时49分，Inozyme Pharma, Inc.股票出现异动，股价快速上涨5.10%。Inozyme Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.97%。其相关个股中，Cingulate Inc.、Tempest Therapeutics, Inc.、Scisparc Ltd.涨幅较大，Cingulate Inc.、Scisparc Ltd.、Altamira Therapeutics Ltd.较为活跃，换手率分别为6153.71%、2016.08%、543.81%，振幅较大的相关个股有Seastar Medical Holding Corp C/Wts 28/10/2027 、Tempest Therapeutics, Inc.、Cingulate Inc.，振幅分别为103.98%、79.83%、70.46%。Inozyme Pharma, Inc.公司简介：Inozyme Pharma 是一家临床阶段的罕见病生物制药公司，致力于开发用于治疗影响血管、软组织和骨骼疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815224909ab5ddb6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815224909ab5ddb6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2459717456","title":"Inozyme Pharma, Inc.盘中异动 急速拉升5.25%报4.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459717456","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459717456?lang=zh_cn&edition=full","pubTime":"2024-08-14 21:30","pubTimestamp":1723642256,"startTime":"0","endTime":"0","summary":"北京时间2024年08月14日21时30分，Inozyme Pharma, Inc.股票出现波动，股价大幅上涨5.25%。Inozyme Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Conduit Pharmaceuticals Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Genprex, Inc.涨幅较大，Conduit Pharmaceuticals Inc.、Viracta Therapeutics, Inc.、Genprex, Inc.较为活跃，换手率分别为48.88%、42.37%、19.28%，振幅较大的相关个股有Genprex, Inc.、Cadrenal Therapeutics, Inc.、Verrica制药，振幅分别为8.21%、7.86%、7.78%。Inozyme Pharma, Inc.公司简介：Inozyme Pharma 是一家临床阶段的罕见病生物制药公司，致力于开发用于治疗影响血管、软组织和骨骼疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081421305698e34ecf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081421305698e34ecf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2459092399","title":"Inozyme Pharma, Inc.盘中异动 股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459092399","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459092399?lang=zh_cn&edition=full","pubTime":"2024-08-13 21:33","pubTimestamp":1723555990,"startTime":"0","endTime":"0","summary":"北京时间2024年08月13日21时33分，Inozyme Pharma, Inc.股票出现波动，股价快速拉升5.07%。Inozyme Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。Inozyme Pharma, Inc.公司简介：Inozyme Pharma 是一家临床阶段的罕见病生物制药公司，致力于开发用于治疗影响血管、软组织和骨骼疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240813213310aefe9ef7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240813213310aefe9ef7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2457844452","title":"Inozyme Pharma, Inc.盘中异动 股价大涨8.92%报5.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457844452","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457844452?lang=zh_cn&edition=full","pubTime":"2024-08-07 21:30","pubTimestamp":1723037448,"startTime":"0","endTime":"0","summary":"北京时间2024年08月07日21时30分，Inozyme Pharma, Inc.股票出现波动，股价急速上涨8.92%。Inozyme Pharma, Inc.股票所在的生物技术行业中，整体涨幅为1.23%。其相关个股中，G1 Therapeutics, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 、Aditxt, Inc.涨幅较大，Scorpius Holdings, Inc.、Aditxt, Inc.、Silo Pharma, Inc.较为活跃，换手率分别为253.31%、106.10%、41.16%，振幅较大的相关个股有Enanta Pharmaceuticals, Inc.、天境生物、Inozyme Pharma, Inc.，振幅分别为11.92%、10.38%、7.01%。Inozyme Pharma, Inc.公司简介：Inozyme Pharma 是一家临床阶段的罕见病生物制药公司，致力于开发用于治疗影响血管、软组织和骨骼疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807213048af966880&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807213048af966880&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2457023514","title":"Inozyme Pharma Inc 报告截至 1 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2457023514","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457023514?lang=zh_cn&edition=full","pubTime":"2024-08-06 21:51","pubTimestamp":1722952295,"startTime":"0","endTime":"0","summary":"   * Inozyme Pharma Inc   报告，截至1月底的季度调整后每股亏损44美分，低于去年同期的每股-35美分。七位分析师对该季度的平均预期是每股亏损 39 美分。华尔街预期为每股-40美分至-35美分。* Inozyme Pharma Inc公布的季度每股收益为亏损44美分。* Inozyme Pharma Inc的股价本季度上涨了5.4%，今年迄今为止上涨了10.3%。8月6日 - 预测变化   * 过去三个月，分析师的平均盈利预期下降了约2.2%。华尔街对 Inozyme Pharma Inc 的 12 个月目标价中位数为 15.00 美元。本摘要由 LSEG 8 月 6 日 01:51 p.m. UTC 数据机器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Inozyme Pharma Inc 报告截至 1 月的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2457874023","title":"Inozyme Pharma, Inc.盘中异动 早盘急速跳水5.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457874023","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457874023?lang=zh_cn&edition=full","pubTime":"2024-08-06 21:42","pubTimestamp":1722951721,"startTime":"0","endTime":"0","summary":"北京时间2024年08月06日21时42分，Inozyme Pharma, Inc.股票出现异动，股价快速跳水5.96%。Inozyme Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。其相关个股中，Vbi Vaccines, Inc.、Tenax Therapeutics, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 涨幅较大，Tenax Therapeutics, Inc.、Vbi Vaccines, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为909.15%、520.45%、232.14%，振幅较大的相关个股有Vbi Vaccines, Inc.、Tenax Therapeutics, Inc.、Actinium Pharmaceuticals, Inc. ，振幅分别为143.08%、29.11%、27.81%。Inozyme Pharma, Inc.公司简介：Inozyme Pharma 是一家临床阶段的罕见病生物制药公司，致力于开发用于治疗影响血管、软组织和骨骼疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240806214201aefd85e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240806214201aefd85e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2457674041","title":"Inozyme Pharma: 截至2024年6月30日的现金、现金等价物和短期投资预计能够支持运营至2025年第四季度。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457674041","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457674041?lang=zh_cn&edition=full","pubTime":"2024-08-06 20:32","pubTimestamp":1722947534,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2457104134","title":"Inozyme Pharma二季度净利润美元指数为-2700万。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457104134","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457104134?lang=zh_cn&edition=full","pubTime":"2024-08-06 20:30","pubTimestamp":1722947401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["JPYmain","CADmain","MEURmain","EUO","FXY","YCS","CHFmain","AUDmain","FXB","FXA","MGBPmain","BK4139","FXE","EURmain","MAUDmain","GBPmain","INZY","USDindex.FOREX","FXF","NZDmain","FXC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inozyme.com","stockEarnings":[{"period":"1week","weight":-0.1634},{"period":"1month","weight":-0.3613},{"period":"3month","weight":-0.2511},{"period":"6month","weight":-0.2543},{"period":"1year","weight":0.0719},{"period":"ytd","weight":-0.1948}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Inozyme Pharma, Inc.根据特拉华州法律成立于2015年9月。该公司是一家罕见的疾病生物制药公司，致力于开发新颖的疗法来治疗影响血管，软组织和骨骼的异常矿化疾病。通过对矿化所涉及的生物途径的深入了解，该公司致力于开发治疗剂以解决这些使人衰弱的疾病的根本原因。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.398674},{"month":2,"riseRate":0.5,"avgChangeRate":0.035032},{"month":3,"riseRate":0.5,"avgChangeRate":0.231994},{"month":4,"riseRate":0,"avgChangeRate":-0.140893},{"month":5,"riseRate":0.5,"avgChangeRate":-0.000114},{"month":6,"riseRate":0.5,"avgChangeRate":0.047361},{"month":7,"riseRate":0.25,"avgChangeRate":-0.006548},{"month":8,"riseRate":0.2,"avgChangeRate":0.036393},{"month":9,"riseRate":0,"avgChangeRate":-0.135388},{"month":10,"riseRate":0,"avgChangeRate":-0.227258},{"month":11,"riseRate":0.4,"avgChangeRate":-0.019483},{"month":12,"riseRate":0.25,"avgChangeRate":-0.129297}],"exchange":"NASDAQ","name":"Inozyme Pharma","nameEN":"Inozyme Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inozyme Pharma(INZY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Inozyme Pharma(INZY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Inozyme Pharma,INZY,Inozyme Pharma股票,Inozyme Pharma股票老虎,Inozyme Pharma股票老虎国际,Inozyme Pharma行情,Inozyme Pharma股票行情,Inozyme Pharma股价,Inozyme Pharma股市,Inozyme Pharma股票价格,Inozyme Pharma股票交易,Inozyme Pharma股票购买,Inozyme Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inozyme Pharma(INZY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Inozyme Pharma(INZY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}